Answers are grounded in this paper and cite their sources.
Shows that 4′-hydroxyflavanone suppresses SREBP activation and lipid synthesis in human hepatoma cells, suggesting therapeutic potential for hepatic steatosis.
Sterol regulatory element-binding proteins (SREBPs) are major transcription factors that regulate the expression of genes involved in fatty acid and cholesterol biosynthesis. Here we show that 4'-hydroxyflavanone (4'-HF) impairs the fatty acid synthase promoter activity and reduces the activation of SREBPs and their target gene expression in human hepatoma Huh-7 cells. Moreover, 4'-HF suppresses de novo fatty acid and cholesterol synthesis. This study identifies 4'-HF as an inhibitor of SREBP maturation and lipid synthesis, and provides evidence that 4'-HF may have major potential as a pharmaceutical preparation against hepatic steatosis and dyslipidemia.
No takes yet. Share an insight, caveat, or question.
Miyata et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: